At the second BIOTECHMED conference held in Gelendzhik, representatives of Nacimbio, part of Rostec State Corporation, participated in panel discussions related to vaccinal prevention and expansion of the National Immunization Schedule. Within the framework of discussions, special attention was paid to the need for transition to multicomponent prophylactic drugs.
“Today, for the immunization for 2-3 indications a child can receive up to 10 injections. If we plan to expand the National Schedule, then, first of all, we need to work on modern multi-component drugs. Only the transition from mono- to multicomponent vaccines will allow to reduce the injection load and get a “window” for further increase in the list of the National Immunization Schedule,” told the president of the FORT biopharmaceutical company, Anton Katlinskiy.
Following the global trends, the companies included in the Nacimbio periphery have been actively working on new combination drugs for a few years now. “Transition to polyvaccines is an issue requiring comprehensive solution. Today we already see positive trend: National Immunization Schedule includes four-component vaccine DTaP-Hep B, we have filed documents for the registration of the five-component vaccine DTaP-Hep B+Hib with whole-cell and cell-free pertussis components,” stated Kirill Gaidash, officer-in-charge of the Microgen NPO. “Another example is the MMR vaccine (measles, rubella, parotitis), which we plan to register by 2018 and offer it to the Ministry of Health of Russia to consider its possible inclusion in the National Schedule.”
At BIOTECHMED, the role of Nacimbio as the exclusive vaccine supplier for National Immunization Schedule and results of several years of drug supplies for the needs of the Ministry of Health of Russia were also discussed. “For the holding, the government is the main consumer of products, and the order received from our main buyer prevails. It allows planning the volumes for a certain period, creating your own performance targets and coordinating the developments of other pharmaceutical manufacturers, including for the purpose of market launch of multicomponent drugs,” stated Anton Katlinskiy in his speech.
